BIOT

Biotech Acquisition Company Class A Ordinary Shares
BIOT

Overview Fund Activity
Delisted

BIOT was delisted on the 2nd of February, 2023.

Back to rankings

76 hedge funds and large institutions have $211M invested in Biotech Acquisition Company Class A Ordinary Shares in 2021 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
76
Holders Change
+18
Holders Change %
+31.03%
% of All Funds
1.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
9
Reduced
10
Closed
8
Calls
$96K
Puts
–
Net Calls
+$96K
Net Calls Change
-$2K

Top Buyers

1
AC
Aristeia Capital
Connecticut
$11.3M
2
CM
Cohanzick Management
New York
$7.86M
3
RA
RiverPark Advisors
New York
$7.86M
4
Marshall Wace
Marshall Wace
United Kingdom
$9.02M
5
WCMNY
Westchester Capital Management (New York)
New York
$5.12M

Top Sellers

1
SRCM
Sage Rock Capital Management
New York
$0
2
ACM
Atalaya Capital Management
New York
$68K
3
MP
Mangrove Partners
Connecticut
$0
4
CC
Centiva Capital
New York
$0
5
PP
Paloma Partners
Connecticut
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
TRCT
76
Tower Research Capital (TRC)
New York
$2K +$2K +195 New
SRCM
77
Sage Rock Capital Management
New York
– -$5.59M -573,800 Closed
MP
78
Mangrove Partners
Connecticut
– -$2.92M -300,000 Closed
CC
79
Centiva Capital
New York
– -$2.42M -248,000 Closed
PP
80
Paloma Partners
Connecticut
– -$498K -51,100 Closed
TI
81
Telemetry Investments
New York
– -$390K -40,000 Closed
PI
82
PEAK6 Investments
Illinois
– -$137K -14,093 Closed
VCM
83
Vivaldi Capital Management
Illinois
– -$97K -10,000 Closed
S
84
SignatureFD
Georgia
– -$1K -72 Closed
1 2 3
4